Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670561 | 0.90 | DRD4 (0.47) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL8302741 | 0.78 | TP53 (0.46) | ALDH1A1KMT2ANR3C2MMP12DRD4 | |
| SCHEMBL8306454 | 0.78 | MMP12 (0.38) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL8303991 | 0.78 | MAPT (0.48) | KMT2ANR3C2MMP12DRD4DRD2 | |
| SCHEMBL8301735 | 0.78 | MMP12 (0.38) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL30405408 | 0.77 | ALDH1A1 (0.60) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| Bromide SCHEMBL8305153 | 0.77 | MAPT (0.37) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL5213064 | 0.76 | NR3C2 (0.62) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL8307617 | 0.76 | PARP1 (0.45) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 | |
| SCHEMBL8303332 | 0.76 | PARP1 (0.45) | ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9522150-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-0548254-B1 | 6- OR 7-(IMIDAZOLIDIN-2-YLIDENEAMINO)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN INC (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0548254-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004345-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5091528-A | Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors | ALLERGAN, INC. (US) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ADRB1, ADRB2, ADRA2C | ALDH1A1 497/4885KMT2A 3759/4885SMN1; SMN2 2878/4885 |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ADRB1, ADRB2, ADRA2C | ALDH1A1 497/4885KMT2A 3759/4885SMN1; SMN2 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.